Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

Jinkai Zang,Bingjie Zhou,Dimitri Lavillette,Chenjian Gu,Di Qu,Youhua Xie,Zhenghong Yuan,Yong Yang,Qiang Deng,Chao Zhang,Hong Tang,Rong Zhang,Zhong Huang,Shiqi Xu,Lulu Bai

doi:10.1038/s41421-020-00199-1

Abstract

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

Highlights

Pandemic is a serious public health crisis, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
We evaluated the possibility of developing SARS-CoV-2 receptor-binding domain (RBD)-based vaccines
To rapidly evaluate vaccine potential of SARS2-RBD, a pilot mouse immunization study was performed with recombinant RBD/mouse IgG1-Fc fusion protein (RBDFc) as immunogen

Summary

Introduction

Pandemic is a serious public health crisis, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recombinant RBD proteins of SARS-CoV and MERSCoV have been shown to potently induce protective neutralizing antibodies and are considered promising vaccine candidates[6,7]. All three antisera dosedependently reacted with His-tagged SARS2-RBD in ELISA, whereas control sera from a naïve mouse did not show significant reactivity (Supplementary Fig. S1a). Anti-RBD-Fc sera #1 dose-dependently inhibited binding between recombinant ACE2-Fc fusion protein and His-tagged SARS2RBD in competition ELISA (Supplementary Fig. S1b), indicating that the antisera contain antibodies targeting

Results

Conclusion